Information Journal Paper
APA:
Copy. (2019). Fusion of thymosin alpha 1 with mutant IgG1 CH3 prolongs halflife and enhances antitumor effects in vivo. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 74(-), 0-0. SID. https://sid.ir/paper/686973/en
Vancouver:
Copy. Fusion of thymosin alpha 1 with mutant IgG1 CH3 prolongs halflife and enhances antitumor effects in vivo. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY[Internet]. 2019;74(-):0-0. Available from: https://sid.ir/paper/686973/en
IEEE:
Copy, “Fusion of thymosin alpha 1 with mutant IgG1 CH3 prolongs halflife and enhances antitumor effects in vivo,” INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, vol. 74, no. -, pp. 0–0, 2019, [Online]. Available: https://sid.ir/paper/686973/en